Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells

被引:24
|
作者
Yamashita, Naoya [1 ]
Saito, Nao [1 ]
Zhao, Shuai [1 ]
Terai, Kensuke [2 ,3 ]
Hiruta, Nobuyuki [2 ,3 ]
Park, Youngjin [4 ,5 ]
Bujo, Hideaki [2 ]
Nemoto, Kiyomitsu [1 ]
Kanno, Yuichiro [5 ]
机构
[1] Toho Univ, Fac Pharmaceut Sci, Dept Mol Toxicol, Miyama 2-2-1, Funabashi, Chiba 2748510, Japan
[2] Toho Univ, Sakura Med Ctr, Dept Clin Lab & Expt Res Med, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[3] Toho Univ, Sakura Med Ctr, Dept Surg Pathol, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[4] Toho Univ, Sakura Med Ctr, Dept Surg, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[5] Tohoku Med & Pharmaceut Univ, Dept Breast & Endocrine Surg, Fukumuro 1-15-1, Sendai, Miyagi 9838536, Japan
基金
日本学术振兴会;
关键词
Breast cancer; AhR; Heregulin; HER2; HER3; MAMMOSPHERE FORMATION; EXPRESSION; REVEALS; TRANSCRIPTION; METASTASIS; ACTIVATION; NETWORK; GROWTH; ERBB3; HER2;
D O I
10.1016/j.yexcr.2018.02.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER2 overexpression accounts for approximately 15-20% of all breast cancers. We have shown that HER2 overexpression leads to elevated expression of the aryl hydrocarbon receptor (AhR) in breast cancer cells. In this study, firstly, we showed that AhR expression was up-regulated by treatment with the HER3 ligand heregulin (HRG) in HER2-overexpressing breast cancer cell lines. Induction of AhR was mediated by transcriptional activation of the region of AhR promoter corresponding to -190 to -100 bp. In addition, HRG treatment elicited nuclear translocation of AhR. To investigate the role of AhR in HRG-HER2/HER3 signaling in HER2-overexpressing cells, we established AhR knockout (KO) HER2-overexpressing cells to perform wound-healing assays. HRG-induced cell migration was markedly attenuated by AhR KO. HRG-induced cell migration was associated with increased expression of the inflammatory cytokines interleukin (IL)-6 and IL-8 in wild type cells, but not in AhR KO cells. These results elucidate that AhR is an important factor for the malignancy in HER2-overexpressing breast cancers.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 50 条
  • [21] ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
    Steinhaeuser, Sophie Sarah
    Morera, Erika
    Budkova, Zuzana
    Schepsky, Alexander
    Wang, Qiong
    Rolfsson, Ottar
    Riedel, Angela
    Krueger, Aileen
    Hilmarsdottir, Bylgja
    Maelandsmo, Gunhild Mari
    Valdimarsdottir, Bryndis
    Sigurdardottir, Anna Karen
    Agnarsson, Bjarni Agnar
    Jonasson, Jon Gunnlaugur
    Ingthorsson, Saevar
    Traustadottir, Gunnhildur Asta
    Oskarsson, Thordur
    Gudjonsson, Thorarinn
    LABORATORY INVESTIGATION, 2020, 100 (07) : 928 - 944
  • [22] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Clara Natoli
    Patrizia Vici
    Isabella Sperduti
    Antonino Grassadonia
    Giancarlo Bisagni
    Nicola Tinari
    Andrea Michelotti
    Germano Zampa
    Stefania Gori
    Luca Moscetti
    Michele De Tursi
    Michele Panebianco
    Maria Mauri
    Ilaria Ferrarini
    Laura Pizzuti
    Corrado Ficorella
    Riccardo Samaritani
    Lucia Mentuccia
    Stefano Iacobelli
    Teresa Gamucci
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1229 - 1240
  • [23] The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression
    Xu, FJ
    Yu, YH
    Le, XF
    Boyer, C
    Mills, GB
    Bast, RC
    CLINICAL CANCER RESEARCH, 1999, 5 (11) : 3653 - 3660
  • [24] Apoptotic Cell Death Induced by Genistein and Quercetin Inhibiting NF-kB Signaling in HER2-overexpressing Breast Cancer Cells
    Cheon, C. H.
    Seo, H. S.
    Choi, H. S.
    Kim, J. H.
    Kim, G. J.
    Jeon, C. Y.
    Jin, D. H.
    Ko, S. G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S63 - S63
  • [25] Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer
    Sanjay P. Bagaria
    Partha S. Ray
    Jinhua Wang
    Luisa Kropcho
    Alice Chung
    Myung-Shin Sim
    Jaime M. Shamonki
    Silvana Martino
    Xiaojiang Cui
    Armando E. Giuliano
    Annals of Surgical Oncology, 2012, 19 : 935 - 940
  • [26] HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
    Loi, Sherene
    de Azambuja, Evandro
    Pugliano, Lina
    Sotiriou, Christos
    Piccart, Martine J.
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 547 - 558
  • [27] Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo
    Nonagase, Yoshikane
    Yonesaka, Kimio
    Watanabe, Satomi
    Haratani, Koji
    Takahama, Takayuki
    Takegawa, Naoki
    Ueda, Hiroto
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Sakamoto, Haruka
    Tamura, Takao
    Nakagawa, Kazuhiko
    Tsurutani, Junji
    CANCER RESEARCH, 2016, 76
  • [28] Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer
    Bagaria, Sanjay P.
    Ray, Partha S.
    Wang, Jinhua
    Kropcho, Luisa
    Chung, Alice
    Sim, Myung-Shin
    Shamonki, Jaime M.
    Martino, Silvana
    Cui, Xiaojiang
    Giuliano, Armando E.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (03) : 935 - 940
  • [29] Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer
    Hernandez-Garcia, Susana
    Gonzalez, Verena
    Sanz, Eduardo
    Pandiella, Atanasio
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2015, 67 (07): : 1159 - 1169
  • [30] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Natoli, Clara
    Vici, Patrizia
    Sperduti, Isabella
    Grassadonia, Antonino
    Bisagni, Giancarlo
    Tinari, Nicola
    Michelotti, Andrea
    Zampa, Germano
    Gori, Stefania
    Moscetti, Luca
    De Tursi, Michele
    Panebianco, Michele
    Mauri, Maria
    Ferrarini, Ilaria
    Pizzuti, Laura
    Ficorella, Corrado
    Samaritani, Riccardo
    Mentuccia, Lucia
    Iacobelli, Stefano
    Gamucci, Teresa
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1229 - 1240